Komentář k lékovému profilu
Rifaximin – terapeutické vlastnosti

Czech version

Authors: P. Frič
Authors‘ workplace: Interní klinika 1. LF UK a ÚVN – VFN Praha
Published in: Gastroent Hepatol 2017; 71(4): 355
Category: Commentary

Sources

1. Kamenář D, Špičák J. Rifaximin v léčbě gastrointestinálních onemocnění. Gastroent Hepatol 2014; 68 (3): 230–236.

2. Bortlík M. Rifaximin – terapeutické vlastnosti. Gastroent Hepatol 2017; 71 (3): 271–272. doi: 10.14735/amgh2017271.

3. Cheng J, Shah YM, Ma X et al. Therapeutic role of Rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010; 335 (1): 32–41. doi: 10.1124/jpet.110.170225.

4. Cheng J, Shah M, Gonzalez FJ. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 2012; 33 (6): 323–330. doi: 10.1016/j.tips.2012.03.003.

5. Mencarelli A, Migliorati M, Barbanti M et al. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 2010; 80 (11): 1700–1707. doi: 10.1016/j.bcp.2010. 08.022.

6. Smutny T, Mani S, Pavek P. Post-translational and post-transcriptional modifications of pregnane-X-receptor (PXR) in regulation of cytochrome P450 superfamily. Curr Drug Metab 2013; 4 (10): 1059–1069.

7. Smutny T, Bitman M, Urban M et al. UO126, a mutagen-activated protein kinase 1 and 2 (MEK 1 and 2) inhibitor selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells. Arch Toxicol 2014; 88 (12): 2243–2259. doi: 10.1007/ s00204-014-1254-2.

8. Smutny T, Pavek P. Resveratrol as an inhibitor of pregnane X receptor (PXR): another lesson in PXR antagonism. J Pharmacol Sci 2014; 126 (2): 177–178.

9. Hyrsova L, Smutny T, Carazo A et al. The pregnane-X-receptor down-regulates organic cation transporter 1 (SLC22A1) by competing for („squelching“) SRC-1 coactivator. Br Pharmacol 2016; 173 (10): 1703–1715. doi: 10.1111/bph.13472.